Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Isosteviol is a diterpenoid compound derived from the hydrolysis of stevioside, a natural sweetener found in Stevia rebaudiana. It exhibits multiple biological activities, including inhibition of DNA polymerases and human DNA topoisomerase II, which are enzymes involved in DNA replication and cell proliferation. Isosteviol has demonstrated anti-inflammatory, antioxidant, antibacterial, anticancer, and anti-tuberculosis effects in preclinical studies. It also retards the growth of various human cancer cells and inhibits inflammation induced by TPA (12-O-tetradecanoylphorbol-13-acetate). In addition to its pharmaceutical potential for chronic diseases such as cancer and inflammation-related conditions, isosteviol is used as a low-calorie natural sweetener in food products and has applications in cosmetics for its moisturizing properties[1][4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on isosteviol.